Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Multi-target TMS for Schizophrenia Negative Symptoms

NCT: NCT07559084 · RECRUITING

NCT IDNCT07559084
StatusRECRUITING
Start Date2026-05-01
Completion2028-01-30

Brief Summary

This randomized controlled trial (RCT) is the first to evaluate the efficacy and safety of a multi-target TMS protocol targeting the left dorsolateral prefrontal cortex (L-DLPFC), left inferior parietal lobule (L-IPL), and right orbitofrontal cortex (R-OFC) for negative symptoms of schizophrenia.

Frequently Asked Questions

What is Multi-target TMS for Schizophrenia Negative Symptoms?

Multi-target TMS for Schizophrenia Negative Symptoms is a clinical trial registered under NCT07559084. Current status: RECRUITING.

What is the status of NCT07559084?

The current status of NCT07559084 (Multi-target TMS for Schizophrenia Negative Symptoms) is: RECRUITING.

When did Multi-target TMS for Schizophrenia Negative Symptoms start?

Multi-target TMS for Schizophrenia Negative Symptoms started on 2026-05-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑